September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Phototherapy helps some patients with alopecia areata regrow hair, especially those with hair at treatment start and less severe forms of the condition.
March 2023 in “Pakistan Journal of Medical & Health Sciences” Vitamin D analogues can significantly help hair regrowth in Alopecia Areata patients.
3 citations
,
September 2022 in “Archives of dermatological research” The fractional carbon dioxide laser is a safe and effective treatment for alopecia areata and works better than betamethasone valerate cream alone.
December 2023 in “International journal of research in dermatology” Adding PRP to topical mometasone improves and speeds up alopecia areata treatment.
1 citations
,
December 2022 in “Journal of cosmetic dermatology” The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.
19 citations
,
January 2021 in “Journal of the American Academy of Dermatology” Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
Human placental extract effectively and safely improves melasma, ulcers, and alopecia areata.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
1 citations
,
September 2023 in “Dermatology and Therapy” Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
11 citations
,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
2 citations
,
August 2022 in “JAAD case reports” COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.
2 citations
,
January 2018 in “International journal of research in dermatology” Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
1 citations
,
August 2018 in “Journal of the American Academy of Dermatology” Children with autoimmune hair loss have similar vitamin D levels to healthy kids, suggesting no extra screening is needed.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
October 2025 in “International Journal of Dermatology” Baricitinib is a safe and effective treatment for alopecia areata, with better results in patients with lower initial severity, shorter disease duration, and longer treatment.
July 2025 in “Pakistan Journal of Intensive Care Medicine” Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
June 2025 in “Indus journal of bioscience research.” Oral tofacitinib is more effective than oral minoxidil for treating alopecia areata.
June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
May 2024 in “JEADV Clinical Practice” A change in SALT scores of 42 or 43 indicates meaningful improvement in alopecia areata treatment.